AKEBIA THERAPEUTICS, INC. Investment Income, Interest
AKEBIA THERAPEUTICS, INC. (AKBA) reported Investment Income, Interest of $842.00 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2017-11-08
- AKEBIA THERAPEUTICS, INC. investment income, interest for the quarter ending 2017-09-30 was $842.00K, a 284.47% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. investment income, interest for the quarter ending 2017-06-30 was $608.00K, a 125.19% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. investment income, interest for the quarter ending 2017-03-31 was $435.00K, a 85.90% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. investment income, interest for the quarter ending 2016-12-31 was $179.00K, a 11.87% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. investment income, interest for fiscal 2016 was $901.00K, a 76.67% increase from fiscal 2015.
- AKEBIA THERAPEUTICS, INC. investment income, interest for fiscal 2015 was $510.00K, a 147.57% increase from fiscal 2014.
- AKEBIA THERAPEUTICS, INC. investment income, interest for fiscal 2014 was $206.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2017-09-30 | $842.00K 10-Q · filed 2017-11-08 | $1.45M derived: sum of 2 quarters · filed 2017-11-08 | $1.89M 10-Q · filed 2017-11-08 | $2.06M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-06-30 | $608.00K 10-Q · filed 2017-08-08 | $1.04M 10-Q · filed 2017-08-08 | $1.22M derived: sum of 3 quarters · filed 2017-08-08 | $1.44M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-03-31 | $435.00K 10-Q · filed 2017-05-09 | $614.00K derived: sum of 2 quarters · filed 2017-05-09 | $833.00K derived: sum of 3 quarters · filed 2017-11-08 | $1.10M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $398.00K derived: sum of 2 quarters · filed 2017-11-08 | $668.00K derived: sum of 3 quarters · filed 2017-11-08 | $901.00K 10-K · filed 2017-03-06 |
| 2016-09-30 | $219.00K 10-Q · filed 2017-11-08 | $489.00K derived: sum of 2 quarters · filed 2017-11-08 | $722.00K 10-Q · filed 2017-11-08 | $883.00K derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $270.00K 10-Q · filed 2017-08-08 | $504.00K 10-Q · filed 2017-08-08 | $664.00K derived: sum of 3 quarters · filed 2017-08-08 | $803.00K derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $234.00K 10-Q · filed 2017-05-09 | $394.00K derived: sum of 2 quarters · filed 2017-05-09 | $533.00K derived: sum of 3 quarters · filed 2017-05-09 | $649.00K derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $299.00K derived: sum of 2 quarters · filed 2017-03-06 | $415.00K derived: sum of 3 quarters · filed 2017-03-06 | $510.00K 10-K · filed 2017-03-06 |
| 2015-09-30 | $139.00K 10-Q · filed 2016-11-09 | $255.00K derived: sum of 2 quarters · filed 2016-11-09 | $350.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $116.00K 10-Q · filed 2016-08-08 | $212.00K 10-Q · filed 2016-08-08 | ||
| 2014-12-31 | $206.00K 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |